Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

We previously reported inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity in 1-5% of unvaccinated patients with life-threatening COVID-19, and auto-antibodies against type I IFN in another 15-20% of cases. We report here a genome-wide rare variant burden association analysis in 3,269 unvaccinated patients with life-threatening COVID-19 (1,301 previously reported and 1,968 new patients), and 1,373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. A quarter of the patients tested had antibodies against type I IFN (234 of 928) and were excluded from the analysis. No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was , with an OR of 27.68 (95%CI:1.5-528.7, 1.1×10 ), in analyses restricted to biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR=3.70 [95%CI:1.3-8.2], 2.1×10 ). Adding the recently reported COVID-19 locus strengthened this enrichment, particularly under a recessive model (OR=19.65 [95%CI:2.1-2635.4]; 3.4×10 ). When these 14 loci and were considered, all individuals hemizygous ( =20) or homozygous ( =5) for pLOF or bLOF variants were patients (OR=39.19 [95%CI:5.2-5037.0], =4.7×10 ), who also showed an enrichment in heterozygous variants (OR=2.36 [95%CI:1.0-5.9], =0.02). Finally, the patients with pLOF or bLOF variants at these 15 loci were significantly younger (mean age [SD]=43.3 [20.3] years) than the other patients (56.0 [17.3] years; 1.68×10 ). Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old.